$1.26
0[0.00%]
Last update: 4:00PM Get Real Time Here
Ikena Oncology
(NASDAQ:IKNA)Ikena Oncology Stock (NASDAQ:IKNA), Analyst Ratings, Price Targets, Predictions
Ikena Oncology Inc has a consensus price target of $13.88, established from looking at the 23 latest analyst ratings. The last 3 analyst ratings were released from HC Wainwright & Co., HC Wainwright & Co., and Wedbush on March 19, 2024, March 12, 2024, and January 19, 2024. With an average price target of $10 between HC Wainwright & Co., HC Wainwright & Co., and Wedbush, there's an implied 681.25% upside for Ikena Oncology Inc from these 3 analyst ratings.
Analyst Firms Making Recommendations1
HC Wainwright & Co.
Wedbush
Credit Suisse
HC Wainwright & Co.
Credit Suisse
1calculated from analyst ratings published within the last 3 years
Analyst Ratings for Ikena Oncology
date | ticker | Buy Now | Company | Current price | Upside/Downside | Analyst Firm | Analyst & % Accurate | Price Target Change | Rating Change | Previous / Current Rating | Get Alert |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 03/19/2024 | IKNA | Buy Now | Ikena Oncology | $1.28 | 759.38% | HC Wainwright & Co. | Andres Maldonado | → $11 | Reiterates | Buy → Buy | Get Alert |
| 03/12/2024 | IKNA | Buy Now | Ikena Oncology | $1.28 | 759.38% | HC Wainwright & Co. | Andres Maldonado | $11 → $11 | Maintains | Buy | Get Alert |
| 01/19/2024 | IKNA | Buy Now | Ikena Oncology | $1.28 | 525% | Wedbush | David Nierengarten | → $8 | Reiterates | Outperform → Outperform | Get Alert |
| 01/19/2024 | IKNA | Buy Now | Ikena Oncology | $1.28 | 759.38% | HC Wainwright & Co. | Andres Maldonado | → $11 | Reiterates | Buy → Buy | Get Alert |
| 11/09/2023 | IKNA | Buy Now | Ikena Oncology | $1.28 | 759.38% | HC Wainwright & Co. | Andres Maldonado | $18 → $11 | Maintains | Buy | Get Alert |
| 09/22/2023 | IKNA | Buy Now | Ikena Oncology | $1.28 | 759.38% | Wedbush | David Nierengarten | → $11 | Initiates | → Outperform | Get Alert |
| 08/10/2023 | IKNA | Buy Now | Ikena Oncology | $1.28 | 1306.25% | HC Wainwright & Co. | Andres Maldonado | → $18 | Reiterates | Buy → Buy | Get Alert |
| 08/07/2023 | IKNA | Buy Now | Ikena Oncology | $1.28 | 1306.25% | HC Wainwright & Co. | Andres Maldonado | → $18 | Reiterates | Buy → Buy | Get Alert |
| 05/24/2023 | IKNA | Buy Now | Ikena Oncology | $1.28 | 1306.25% | HC Wainwright & Co. | Andres Maldonado | → $18 | Reiterates | Buy → Buy | Get Alert |
| 05/16/2023 | IKNA | Buy Now | Ikena Oncology | $1.28 | 915.63% | Credit Suisse | Judah Frommer | → $13 | Reiterates | Outperform → Outperform | Get Alert |
| 05/04/2023 | IKNA | Buy Now | Ikena Oncology | $1.28 | 1306.25% | HC Wainwright & Co. | Andres Maldonado | → $18 | Assumes | → Buy | Get Alert |
| 03/17/2023 | IKNA | Buy Now | Ikena Oncology | $1.28 | 1618.75% | HC Wainwright & Co. | Robert Burns | → $22 | Reiterates | → Buy | Get Alert |
| 03/15/2023 | IKNA | Buy Now | Ikena Oncology | $1.28 | 915.63% | Credit Suisse | Judah Frommer | $16 → $13 | Maintains | Outperform | Get Alert |
| 11/29/2022 | IKNA | Buy Now | Ikena Oncology | $1.28 | 1150% | Credit Suisse | Judah Frommer | $18 → $16 | Maintains | Outperform | Get Alert |
| 11/29/2022 | IKNA | Buy Now | Ikena Oncology | $1.28 | 1618.75% | HC Wainwright & Co. | Robert Burns | $26 → $22 | Maintains | Buy | Get Alert |
| 11/08/2022 | IKNA | Buy Now | Ikena Oncology | $1.28 | 1306.25% | Credit Suisse | Judah Frommer | $20 → $18 | Maintains | Outperform | Get Alert |
| 05/13/2022 | IKNA | Buy Now | Ikena Oncology | $1.28 | 1462.5% | Credit Suisse | Judah Frommer | $24 → $20 | Maintains | Outperform | Get Alert |
| 04/13/2022 | IKNA | Buy Now | Ikena Oncology | $1.28 | 1931.25% | HC Wainwright & Co. | Robert Burns | $25 → $26 | Maintains | Buy | Get Alert |
| 12/23/2021 | IKNA | Buy Now | Ikena Oncology | $1.28 | 1853.13% | HC Wainwright & Co. | Robert Burns | → $25 | Initiates | → Buy | Get Alert |
FAQ
What is the target price for Ikena Oncology (IKNA)?
The latest price target for Ikena Oncology (NASDAQ: IKNA) was reported by HC Wainwright & Co. on March 19, 2024. The analyst firm set a price target for $11.00 expecting IKNA to rise to within 12 months (a possible 773.02% upside). 11 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Ikena Oncology (IKNA)?
The latest analyst rating for Ikena Oncology (NASDAQ: IKNA) was provided by HC Wainwright & Co., and Ikena Oncology reiterated their buy rating.
When was the last upgrade for Ikena Oncology (IKNA)?
There is no last upgrade for Ikena Oncology.
When was the last downgrade for Ikena Oncology (IKNA)?
There is no last downgrade for Ikena Oncology.
When is the next analyst rating going to be posted or updated for Ikena Oncology (IKNA)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Ikena Oncology, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Ikena Oncology was filed on March 19, 2024 so you should expect the next rating to be made available sometime around March 19, 2025.
Is the Analyst Rating Ikena Oncology (IKNA) correct?
While ratings are subjective and will change, the latest Ikena Oncology (IKNA) rating was a reiterated with a price target of $0.00 to $11.00. The current price Ikena Oncology (IKNA) is trading at is $1.26, which is within the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.